Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&amp;P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward.   In today’s report we highlight attractive Groups and stocks within Health Care and Services: Pharmaceuticals, Mega- &amp; Large-Cap , Biotech , Diagnostic &amp; Test Products, Diagnostic &amp; Test Services, and Education Svcs., China

Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&amp;P 500 (2,855), DJI (24,681) and Russell 2000 (1,448), ushering-in additional downside. We view these levels as logical areas of potential short-term resistance moving forward.   In today’s report we highlight attractive Groups and stocks within Health Care and Services: Pharmaceuticals, Mega- &amp; Large-Cap , Biotech , Diagnostic &amp; Test Products, Diagnostic &amp; Test Services, and Education Svcs., China

Nasdaq-100 Stock Index / Technical Analysis

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting attractive investment opportunities within each of our 12 Sectors.

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting attractive investment opportunities within each of our 12 Sectors.

U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom

IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

Innovent Biologics Inc / Equity Capital Markets

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, <a href="https://www.smartkarma.com/entities/27452" target="_blank" data-smartkarma-citation="entities:27452:1">Innovent Biologics Inc (1801 HK)</a>'s shares popped 19% on its debut in Hong Kong. Post the first-day share price pop; we advise IPO investors to take money off the table. Our analysis suggests that the current share price already factors in ambitious targets regarding peak market share and terminal EBIT margin for its key late-stage drug (sintilimab).

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped 19% on its debut in Hong Kong. Post the first-day share price pop; we advise IPO investors to take money off the table. Our analysis suggests that the current share price already factors in ambitious targets regarding peak market share and terminal EBIT margin for its key late-stage drug (sintilimab).

Innovent Biologics IPO First-Day: Take Money off the Table

Japan TMT Analyst

Pelham Smithers

Market Intel on Asian Tech with a Japan focus

Pelham Smithers Associates

Founded in 2009, Pelham Smithers Associates (PSA) provides market intelligence on Asian technology, focusing in particular on Japan. The industries covered by our team of specialists are: consumer electronics, telecomms, pharmaceuticals, internet, electronic parts and materials, automotive technology, retail and capital goods. 

Research is provided by the following:
Pelham Smithers: Macro, consumer electronics, telecoms & pharma
Joel Scheiman: Electronics materials / components
Julie Boote: Autos
Will Nestuk: Capital goods, machinery & transportation equipment parts
Thao Nguyen: eCommerce, internet content, marketing & advertising

Equity Bottom-Up

Firms have spent billions of dollars developing a means of reversing Alzheimer's Disease. A new report suggests that they've been looking in the wrong direction. If the report is correct, this is great news for Alzheimer's patients, their families and there carers. It is not so good for the pharmaceutical industry, particularly those companies pushing to get their drugs approved because there is no alternative on the market.

Firms have spent billions of dollars developing a means of reversing Alzheimer's Disease. A new report suggests that they've been looking in the wrong direction. If the report is correct, this is great news for Alzheimer's patients, their families and there carers. It is not so good for the pharmaceutical industry, particularly those companies pushing to get their drugs approved because there is no alternative on the market.

Alzheimer's Disease and the Link with the Herpes Simplex Virus

Founder

Kemp Dolliver, CFA

Cherrystone Hill Research

Recent developments in <a href="https://www.smartkarma.com/entities/22932" target="_blank" data-smartkarma-citation="entities:22932:1">Samsung Biologics Co., (207940 KS)</a>'s business have been mixed with a negative skew. First, partner <a href="https://www.smartkarma.com/entities/26820" target="_blank" data-smartkarma-citation="entities:26820:1">Merck &amp; Co Inc (MRK UN)</a> terminated a product development project, reducing long-term revenue and earnings prospects. Second, recent biosimilar product launches face increased competition relative to prior launches. Third, the CMO business' capacity is expanding dramatically while backlogs have been stagnant. Fourth, accounting controversies are returning to the fore. The company's US$27 billion market cap remains a function of earnings prospects in 4-5 years, which we think are likely to disappoint.

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck &amp; Co Inc (MRK UN) terminated a product development project, reducing long-term revenue and earnings prospects. Second, recent biosimilar product launches face increased competition relative to prior launches. Third, the CMO business' capacity is expanding dramatically while backlogs have been stagnant. Fourth, accounting controversies are returning to the fore. The company's US$27 billion market cap remains a function of earnings prospects in 4-5 years, which we think are likely to disappoint.

United States

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. The Company products are sold in countries around the world. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Eli Lilly & (LLY UN)

S&P 500: Long-Term Oversold

Major indexes broke below the key support levels we were watching on the Nasdaq Composite (8,264), S&P 500 (2,855), DJI (24,681) and Russell...

Vermilion Research

U.S. Equity Strategy: Defensive Areas Weakening; Broad Market Attempting to Bottom

In this report we detail our U.S. investment thesis and provide a detailed technical appraisal of the broad market, as well as highlighting...

Vermilion Research

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Arun George

Alzheimer's Disease and the Link with the Herpes Simplex Virus

Firms have spent billions of dollars developing a means of reversing Alzheimer's Disease. A new report suggests that they've been looking in the...

Pelham Smithers Associates

Samsung BioLogics Update

Recent developments in Samsung Biologics Co., (207940 KS)'s business have been mixed with a negative skew. First, partner Merck & Co Inc (MRK...

Kemp Dolliver, CFA

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)